OptiNose (OPTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OptiNose (OPTN) has a cash flow conversion efficiency ratio of -0.027x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.67 Million) by net assets ($-61.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OPTN market cap for the company's overall valuation and market capitalisation.
OptiNose - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how OptiNose's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OptiNose Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OptiNose ranked by their cash flow conversion efficiency. Explore OptiNose (OPTN) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Champion Building Materials Co Ltd
TW:1806
|
0.027x |
|
First Northwest Bancorp
NASDAQ:FNWB
|
0.009x |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
0.000x |
|
TDM Berhad
KLSE:2054
|
0.043x |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLACF
|
-0.003x |
|
Hongli Group Inc. Ordinary Shares
NASDAQ:HLP
|
0.020x |
|
Flexopack Société Anonyme Commercial and Industrial Plastics Company
AT:FLEXO
|
0.048x |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
-0.003x |
Annual Cash Flow Conversion Efficiency for OptiNose (2015–2024)
The table below shows the annual cash flow conversion efficiency of OptiNose from 2015 to 2024. View OPTN stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-40.36 Million | $-44.89 Million | 1.112x | +369.11% |
| 2023-12-31 | $-86.61 Million | $-20.53 Million | 0.237x | -80.16% |
| 2022-12-31 | $-56.62 Million | $-67.65 Million | 1.195x | -66.19% |
| 2021-12-31 | $-21.77 Million | $-76.94 Million | 3.534x | +127.82% |
| 2020-12-31 | $6.79 Million | $-86.21 Million | -12.700x | -761.19% |
| 2019-12-31 | $61.58 Million | $-90.81 Million | -1.475x | -90.50% |
| 2018-12-31 | $118.61 Million | $-91.82 Million | -0.774x | -235.46% |
| 2017-12-31 | $154.50 Million | $-35.65 Million | -0.231x | +95.92% |
| 2016-12-31 | $-3.84 Million | $21.72 Million | -5.659x | -635.04% |
| 2015-12-31 | $-27.15 Million | $-28.71 Million | 1.058x | -- |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more